Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: September 24, 2008

Drug Name Review Type Class Manufacturer
Patanase New Drug Initial Review Nasal Preparations � Other Alcon
Requip XL New Drug Initial Review Antiparkinson Agents GlaxoSmithKline
Bystolic New Drug Initial Review Beta Blocker Forest
Evamist New Drug Initial Review Hormone Replacement Therapy Ther-Rx
Zamicet New Drug Initial Review Narcotics Hawthorne
Treximet New Drug Appeal Triptans � Combination GlaxoSmithKline
Cimzia New Drug Appeal Biologic Response Modifiers UCB
Suprax Susp PDL Appeal Antibiotics � Cephalosporins Lupin
Symbicort PDL Appeal Inhaled Steroids AstraZeneca
Baraclude PDL Appeal Hepatitis B Agents Bristol-Myers Squibb
Vytorin PDL Appeal Statin Combination Merck Schering Plough